Search Medical Condition
Please enter condition
Please choose location

Foothill Ranch, California Clinical Trials

A listing of Foothill Ranch, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (190) clinical trials

Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

Ten year safety study examining rates of rare adverse events, child bearing issues, effects of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast implants.

Phase N/A

0.59 miles

Learn More »

A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females

This study will evaluate the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c. A placebo control will be utilized.

Phase

0.59 miles

Learn More »

A Study to Evaluate OPTI-BIOME Bacillus Subtilis MB40 on Abdominal Discomfort Gas and Bloating in a Healthy Population

The purpose of this study is to investigate the effects of OPTI-BIOME™ (Bacillus subtilis MB40), a probiotic supplement, on bloating, gas and abdominal discomfort symptoms in otherwise healthy adults.

Phase

0.59 miles

Learn More »

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer.

Patients will be randomised in 1:1 ratio to either olaparib or placebo. Randomisation will be stratified by Hormone receptor status (ER and/or PgR positive/HER2 negative versus TNBC), prior neoadjuvant versus adjuvant chemotherapy and prior platinum use for breast cancer. Randomised patients will receive study treatment for up to a maximum ...

Phase

2.8 miles

Learn More »

Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder

Study LVM-MD-11 is a randomized, double-blind, placebo- and active-controlled, parallel group, fixed-dose study in adolescent patients, ages 12-17 years. The study will be approximately 10 weeks in duration: - 1-week screening/washout period - 8-week double-blind treatment period - 1-week double-blind down-taper period Patients who meet the eligibility criteria at Visit ...

Phase

2.8 miles

Learn More »

Women Informed to Screen Depending on Measures of Risk

For almost 30 years, annual mammograms for women over 40 have been a cornerstone of the US strategy to reduce mortality from breast cancer. A number of advances in the understanding of breast cancer biology, and screening in general, have led to calls to revise and improve national screening strategies ...

Phase N/A

2.8 miles

Learn More »

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee Hip or Shoulder Replacement

A4091064 is a long-term observational follow up study of subjects from tanezumab interventional studies A4091056, A4091057 or A4091058.

Phase

2.8 miles

Learn More »

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at Week 8, compared to giving 2 doses of tanezumab 2.5 mg or 2 ...

Phase

2.8 miles

Learn More »

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

This single arm Phase II trial will assess the best overall response associated with enzalutamide in patients with AR-positive salivary cancers. Given that this will be one of the first prospective studies ever conducted for AR-positive salivary cancers, and there are currently no standard therapies known to be effective for ...

Phase

2.8 miles

Learn More »

Efficacy Safety and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention

This study will evaluate the safety and tolerability of the following doses of AGN-241689: 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.

Phase

2.8 miles

Learn More »